U.S. FDA panel recommends approval of Novo Nordisk diabetes drug

May 24 (Reuters) - A U.S. advisory panel on Tuesday recommended approval of a new diabetes drug made by Novo Nordisk A/S that combines two of its existing treatments in a fixed-dose combination designed to be both effective and convenient.